M
Maartje van Seijen
Researcher at Netherlands Cancer Institute
Publications - 14
Citations - 236
Maartje van Seijen is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 5, co-authored 10 publications receiving 95 citations.
Papers
More filters
Journal ArticleDOI
Ductal carcinoma in situ: to treat or not to treat, that is the question
Maartje van Seijen,Esther H. Lips,Alastair M. Thompson,Serena Nik-Zainal,Andrew Futreal,E. Shelley Hwang,Ellen Verschuur,Joanna Lane,Jos Jonkers,Daniel Rea,Jelle Wesseling,Jelle Wesseling +11 more
TL;DR: The incidence of ductal carcinoma in situ, the perception of risk for developing invasive breast cancer, the current treatment options and the known molecular aspects of progression are reviewed.
Proceedings ArticleDOI
Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis
Christina Yau,Marieke van der Noordaa,Jane Wei,Marie Osdoit,Fabien Reyal,Anne-Sophie Hamy,Marick Laé,Miguel Martín,Maria del Monte,Judy C. Boughey,Rebekah Gould,Jelle Wesseling,Tessa G Steenbruggen,Maartje van Seijen,Gabe S. Sonke,Stephen B. Edge,Stephen John Sammut,Elena Provenzano,Jean Abraham,Peter Hall,Ashley Graham,Lorna Mackintosh,David Cameron,Alice Wang,Priyanka Sharma,Kimberly Cole,Lajos Pusztai,Mi-Ok Kim,Laura van 't Veer,Laura J. Esserman,W. Fraser Symmans +30 more
TL;DR: RCB index and classification was independently and strongly prognostic in all subtypes, and generalizable to multiple practice settings, and long-term prognosis after pCR was similarly excellent in all phenotypic subtypes.
Journal ArticleDOI
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
Tessa G Steenbruggen,Maartje van Seijen,Liselore Maria Janssen,Mette S. van Ramshorst,Erik van Werkhoven,Marie-Jeanne T. F. D. Vrancken Peeters,Jelle Wesseling,Esther H. Lips,Gabe S. Sonke +8 more
TL;DR: The RCB, NRI, and Neo-Bioscore can identify patients with HER2-positive breast cancer with minimal residual disease who have similar 5-year recurrence-free interval compared with patients with pCR.
Journal ArticleDOI
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
Jan Hudecek,Leonie Voorwerk,Maartje van Seijen,Iris Nederlof,Michiel de Maaker,José G van den Berg,Koen Van de Vijver,Karolina Sikorska,Sylvia Adams,Sandra Demaria,Giuseppe Viale,Giuseppe Viale,Torsten O. Nielsen,Sunil S. Badve,Stefan Michiels,William Fraser Symmans,Christos Sotiriou,David L. Rimm,Stephen M. Hewitt,Carsten Denkert,Carsten Denkert,Sibylle Loibl,Sherene Loi,John M. S. Bartlett,John M. S. Bartlett,Giancarlo Pruneri,Deborah A. Dillon,Maggie C.U. Cheang,Andrew Tutt,Jacqueline A. Hall,Zuzana Kos,Roberto Salgado,Marleen Kok,Hugo M. Horlings +33 more
TL;DR: It is demonstrated that a web-based scoring platform can mitigate potential risk factors when including sTILs in clinical trials, and it is argued that this framework can be applied for any future biomarker-driven clinical trial setting.
Journal ArticleDOI
Variability in grading of ductal carcinoma in situ among an international group of pathologists.
Maartje van Seijen,Katarzyna Jóźwiak,Sarah E Pinder,Sarah E Pinder,Allison Hall,Savitri Krishnamurthy,Jeremy Sj Thomas,Laura C. Collins,Jonathan G. Bijron,Joost Bart,Danielle Cohen,Wen Ng,Ihssane Bouybayoune,Hilary Stobart,Jan Hudecek,Michael Schaapveld,Alastair M. Thompson,Esther H. Lips,Jelle Wesseling +18 more
TL;DR: In this paper, the authors evaluated interobserver agreement in grading DCIS between Dutch, British, and American pathologists and found that the inter-observer concordance of grading relates to the expression of the oestrogen receptor (ER) and HER2.